New cancer drug VIR-5525 enters first human trials for EGFR-Positive tumors

NCT ID NCT06960395

Recruiting now Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot be removed or have spread will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colorectal cancer head and neck squamous cell carcinoma non-small cell lung carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR EGFR POSITIVE SOLID TUMORS SOLID TUMOR MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258-4566, United States
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Princess Alexandra Hospital
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.